Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT.

Armstrong-Buisseret, Lindsay, Brittain, Clare, Kai, Joe, David, Miruna, Anstey Watkins, Jocelyn, Ozolins, Mara, Jackson, Louise, Abdali, Zainab, Hepburn, Trish, Griffiths, Frances, Montgomery, Alan, Daniels, Jane, Manley, Alice, Dean, Gillian and Ross, Jonathan Dc (2022) Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT. Health technology assessment (Winchester, England), 26 (2). pp. 1-170. ISSN 2046-4924. This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here -

Full text not available from this repository.
Official URL:



Bacterial vaginosis is a common and distressing condition associated with serious comorbidities. Antibiotic treatment is usually clinically effective in the short term, but recurrence is common and side effects can occur.


The objective is to assess whether or not intravaginal lactic acid gel is clinically effective and cost-effective for treating recurrent bacterial vaginosis compared with oral metronidazole (Flagyl, Sanofi).


This was an open-label, multicentre, parallel-arm, randomised (1 : 1) controlled trial.


This took place in one general practice and 19 sexual health centres in the UK.


Women aged ≥ 16 years with bacterial vaginosis symptoms and one or more episode(s) within the past 2 years took part.


The interventions were 5 ml of intravaginal lactic acid gel taken once daily for 7 days (intervention) or 400-mg oral metronidazole tablets taken twice daily for 7 days (control).


The primary outcome was the resolution of bacterial vaginosis symptoms 14 days after randomisation. The secondary outcomes were time to first recurrence of symptoms; number of recurrences and treatment courses over 6 months; microbiological resolution on microscopy of vaginal smears at week 2; time to resolution of symptoms; tolerability, adherence and acceptability of the treatment; prevalence of concurrent sexually transmitted infections; quality of life; and cost-effectiveness.


Recruitment stopped prior to reaching the target of 1900 participants on recommendation from the Data Monitoring Committee and Trial Steering Committee after a planned review of the results indicated that the research question had been answered. Overall, 518 participants were randomised and primary outcome data were available for 409 participants (79%; 204 in the metronidazole arm, 205 in the lactic acid gel arm). Participant-reported symptom resolution at week 2 was higher with metronidazole (143/204; 70%) than with lactic acid gel (97/205; 47%) (adjusted risk difference -23.2%, 95% confidence interval -32.3% to -14.0%). Recurrence in 6 months in a subset of participants who had initial resolution and were available for follow-up was similar across arms (metronidazole arm: 51/72, 71%; lactic acid gel arm: 32/46, 70%). A higher incidence of some side effects was reported with metronidazole than with lactic acid gel (nausea 32% vs. 8%; taste changes 18% vs. 1%; diarrhoea 20% vs. 6%, respectively). At week 2, the average cost per participant with resolved symptoms was £86.94 (metronidazole), compared with £147.00 (lactic acid gel). Some participants preferred using lactic acid gel even if they perceived it to be less effective than metronidazole.


Loss to follow-up for collection of the primary outcome data was 21% and was similar in both arms. There is a risk of bias owing to missing outcome data at 3 and 6 months post treatment.


A higher initial response was seen with metronidazole than with lactic acid gel, but subsequent treatment failure was common with both. Lactic acid gel was less cost-effective than metronidazole. In general, women disliked taking repeated courses of metronidazole and preferred lactic acid gel, even when they were aware that it was less likely to provide symptom resolution. In the absence of effective curative therapy, further evaluation of non-antibiotic treatments to control the symptoms of recurrent bacterial vaginosis is required to improve quality of life for these patients. Further microbiological analysis of vaginal samples would be useful to identify additional factors affecting response to treatment.


Current Controlled Trials ISRCTN14161293.


This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 26, No. 2. See the NIHR Journals Library website for further project information.

Item Type: Article
Additional Information: This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here -
Subjects: P-Q Language. General science
QW Microbiology. Immunology
WP Gynaecology. Women’s health
Divisions (November 2021 Onwards): Microbiology
Research and Development
Sexual Health
Related URLs:
Depositing User: Mr Richard Rowland
Date Deposited: 01 Feb 2022 15:41
Last Modified: 03 Feb 2022 09:51

Actions (login required)

View Item View Item